208 related articles for article (PubMed ID: 10639310)
1. HPV11 mutant virus-like particles elicit immune responses that neutralize virus and delineate a novel neutralizing domain.
Ludmerer SW; McClements WL; Wang XM; Ling JC; Jansen KU; Christensen ND
Virology; 2000 Jan; 266(2):237-45. PubMed ID: 10639310
[TBL] [Abstract][Full Text] [Related]
2. Characterization of neutralizing epitopes within the major capsid protein of human papillomavirus type 33.
Roth SD; Sapp M; Streeck RE; Selinka HC
Virol J; 2006 Oct; 3():83. PubMed ID: 17014700
[TBL] [Abstract][Full Text] [Related]
3. Human papillomavirus types 6 and 11 have antigenically distinct strongly immunogenic conformationally dependent neutralizing epitopes.
Christensen ND; Kirnbauer R; Schiller JT; Ghim SJ; Schlegel R; Jenson AB; Kreider JW
Virology; 1994 Nov; 205(1):329-35. PubMed ID: 7526536
[TBL] [Abstract][Full Text] [Related]
4. Cellular immune responses to human papillomavirus (HPV)-16 L1 in healthy volunteers immunized with recombinant HPV-16 L1 virus-like particles.
Pinto LA; Edwards J; Castle PE; Harro CD; Lowy DR; Schiller JT; Wallace D; Kopp W; Adelsberger JW; Baseler MW; Berzofsky JA; Hildesheim A
J Infect Dis; 2003 Jul; 188(2):327-38. PubMed ID: 12854090
[TBL] [Abstract][Full Text] [Related]
5. Induction of neutralizing antibodies to papillomaviruses by anti-idiotypic antibodies.
Christensen ND; Reed CA; Cladel NM
Virology; 1995 Jul; 210(2):292-301. PubMed ID: 7542415
[TBL] [Abstract][Full Text] [Related]
6. Two amino acid residues confer type specificity to a neutralizing, conformationally dependent epitope on human papillomavirus type 11.
Ludmerer SW; Benincasa D; Mark GE
J Virol; 1996 Jul; 70(7):4791-4. PubMed ID: 8676509
[TBL] [Abstract][Full Text] [Related]
7. A deletion and point mutation study of the human papillomavirus type 16 major capsid gene.
Varsani A; Williamson AL; Jaffer MA; Rybicki EP
Virus Res; 2006 Dec; 122(1-2):154-63. PubMed ID: 16938363
[TBL] [Abstract][Full Text] [Related]
8. Hybrid papillomavirus L1 molecules assemble into virus-like particles that reconstitute conformational epitopes and induce neutralizing antibodies to distinct HPV types.
Christensen ND; Cladel NM; Reed CA; Budgeon LR; Embers ME; Skulsky DM; McClements WL; Ludmerer SW; Jansen KU
Virology; 2001 Dec; 291(2):324-34. PubMed ID: 11878901
[TBL] [Abstract][Full Text] [Related]
9. Production and characterization of murine IgA monoclonal antibodies to the surface antigens of rhesus rotavirus.
Giammarioli AM; Mackow ER; Fiore L; Greenberg HB; Ruggeri FM
Virology; 1996 Nov; 225(1):97-110. PubMed ID: 8918537
[TBL] [Abstract][Full Text] [Related]
10. A neutralizing epitope of human papillomavirus type 11 is principally described by a continuous set of residues which overlap a distinct linear, surface-exposed epitope.
Ludmerer SW; Benincasa D; Mark GE; Christensen ND
J Virol; 1997 May; 71(5):3834-9. PubMed ID: 9094659
[TBL] [Abstract][Full Text] [Related]
11. [Expression, purification and immunogenicity of human papillomavirus type 11 virus-like particles from Escherichia coli].
Yan C; Li S; Wang J; Wei M; Huang B; Zhuang Y; Li Z; Pan H; Zhang J; Xia N
Wei Sheng Wu Xue Bao; 2009 Nov; 49(11):1527-33. PubMed ID: 20112683
[TBL] [Abstract][Full Text] [Related]
12. A novel human papillomavirus type 6 neutralizing domain comprising two discrete regions of the major capsid protein L1.
McClements WL; Wang XM; Ling JC; Skulsky DM; Christensen ND; Jansen KU; Ludmerer SW
Virology; 2001 Oct; 289(2):262-8. PubMed ID: 11689049
[TBL] [Abstract][Full Text] [Related]
13. Mucosal vaccination with a recombinant Salmonella typhimurium expressing human papillomavirus type 16 (HPV16) L1 virus-like particles (VLPs) or HPV16 VLPs purified from insect cells inhibits the growth of HPV16-expressing tumor cells in mice.
Revaz V; Benyacoub J; Kast WM; Schiller JT; De Grandi P; Nardelli-Haefliger D
Virology; 2001 Jan; 279(1):354-60. PubMed ID: 11145916
[TBL] [Abstract][Full Text] [Related]
14. Generation of monoclonal antibodies of desired specificity using chimeric polyomavirus-derived virus-like particles.
Zvirbliene A; Samonskyte L; Gedvilaite A; Voronkova T; Ulrich R; Sasnauskas K
J Immunol Methods; 2006 Apr; 311(1-2):57-70. PubMed ID: 16516908
[TBL] [Abstract][Full Text] [Related]
15. Minor capsid protein of human genital papillomaviruses contains subdominant, cross-neutralizing epitopes.
Roden RB; Yutzy WH; Fallon R; Inglis S; Lowy DR; Schiller JT
Virology; 2000 May; 270(2):254-7. PubMed ID: 10792983
[TBL] [Abstract][Full Text] [Related]
16. Neutralization determinants of laboratory strains and field isolates of equine arteritis virus: identification of four neutralization sites in the amino-terminal ectodomain of the G(L) envelope glycoprotein.
Balasuriya UB; Patton JF; Rossitto PV; Timoney PJ; McCollum WH; MacLachlan NJ
Virology; 1997 May; 232(1):114-28. PubMed ID: 9185595
[TBL] [Abstract][Full Text] [Related]
17. Human papillomavirus vaccines.
Breitburd F; Coursaget P
Semin Cancer Biol; 1999 Dec; 9(6):431-44. PubMed ID: 10712890
[TBL] [Abstract][Full Text] [Related]
18. [Establishment and application of human papillomavirus type 16 pseudovirions neutralization assay].
Lu WX; Cheng T; Li SW; Pan HR; Shen WT; Chen YX; Zhang T; Zheng Z; Zhang J; Xia NS
Sheng Wu Gong Cheng Xue Bao; 2006 Nov; 22(6):990-5. PubMed ID: 17168325
[TBL] [Abstract][Full Text] [Related]
19. Effect of preexisting neutralizing antibodies on the anti-tumor immune response induced by chimeric human papillomavirus virus-like particle vaccines.
Da Silva DM; Pastrana DV; Schiller JT; Kast WM
Virology; 2001 Nov; 290(2):350-60. PubMed ID: 11883199
[TBL] [Abstract][Full Text] [Related]
20. Modification of human papillomavirus-like particle vaccine by insertion of the cross-reactive L2-epitopes.
Kondo K; Ochi H; Matsumoto T; Yoshikawa H; Kanda T
J Med Virol; 2008 May; 80(5):841-6. PubMed ID: 18360909
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
